Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12–13 February 2020

Autor: Mimi Darko, Ruth A. Karron, Jakob P. Cramer, Melanie Saville, Marion F. Gruber, Gerald Voss, Robert T. Chen, Nicole Lurie, Jeanne-Marie Jacquet, Ajoke Sobanjo-ter Meulen, Charlie Weller, Nadia Tornieporth, Beate Kampmann
Rok vydání: 2021
Předmět:
Emerging infectious diseases
medicine.medical_specialty
LMIC
Low- and middle-income countries
Population
Article
WHO
World Health Organization
EID
Emerging infectious disease
Pregnancy
Lassa virus fever
Pandemic
medicine
GAIA
Global Alignment of Immunisation safety Assessment in pregnancy
GAPPS
Global Alliance for Preventing Prematurity and Stillbirth
Lassa fever
education
LAV
Live attenuated virus vaccine
Disease burden
LASV
Lassa virus
Vaccines
PREVENT
Pregnancy Research Ethics for Vaccines
Epidemics and New Technologies
education.field_of_study
General Veterinary
General Immunology and Microbiology
business.industry
Public Health
Environmental and Occupational Health
LF
Lassa fever
medicine.disease
Clinical trial
Infectious Diseases
Immunization
Maternal immunization
DART
Developmental and reproductive toxicology
DSMB
Data Safety Monitoring Boards
Family medicine
MI
Maternal immunization
Emerging infectious disease
GACVS
Global Advisory Committee on Vaccine Safety
RSV
Respiratory syncytial virus
Molecular Medicine
R&D
Research and development
business
Zdroj: Vaccine
ISSN: 0264-410X
Popis: Infectious diseases may cause serious morbidity and mortality in pregnant women, their foetuses, and infants; the risk associated with any newly emerging infectious disease (EID) is likely unknown at the time of its emergence. While the ongoing SARS-CoV-2 pandemic shows that the development of vaccines against new pathogens can be considerably accelerated, the immunization of pregnant women generally lags behind the general population. Guided by the priority pathogen list for WHO’s R&D Blueprint for Action to Prevent Epidemics, this workshop sought to define the evidence needed for use of vaccines against EIDs in pregnant and lactating women, using Lassa fever as a model. Close to 60 maternal immunization (MI) and vaccine safety experts, regulators, vaccine developers, Lassa fever experts, and investigators from Lassa-affected countries examined the critical steps for vaccine development and immunization decisions for pregnant and lactating women. This paper reports on key themes and recommendations from the workshop. Current practice still assumes the exclusion of pregnant women from early vaccine trials. A shift in paradigm is needed to progress towards initial inclusion of pregnant women in Phase 2 and 3 trials. Several practical avenues were delineated. Participants agreed that vaccine platforms should be assessed early for their suitability for maternal immunization. It was noted that, in some cases, nonclinical data derived from assessing a given platform using other antigens may be adequate evidence to proceed to a first clinical evaluation and that concurrence from regulators may be sought with supporting rationale. For clinical trials, essential prerequisites such as documenting the disease burden in pregnant women, study site infrastructure, capabilities, and staff experience were noted. Early and sustained communication with the local community was considered paramount in any program for the conduct of MI trials and planned vaccine introduction.
Databáze: OpenAIRE
Externí odkaz: